ArticleJournal of exercise rehabilitation2026
Measuring antiaging effects through changes in telomere length after mesenchymal stem cells therapy.
Article in Journal of exercise rehabilitation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Telomere length is a well-known biomarker indicating cellular aging and biological age. Shortening of telomere length is associated with an increased risk of age-related diseases, cellular aging, and reduced re-generative capacity. This study measured changes in peripheral blood telomere length following intravenous mesenchymal stem cells (MSCs) administration. Changes in telomere length (kb/cell) before and after intravenous MSCs treatment were evaluated, and the consistency and extent of telomere elongation were assessed among subjects of various ages, sexes, and treatment durations. Peripheral blood deoxyribo-nucleic acid was extracted and telomere lengths were measured in kb/cell units for a retrospective analysis of 19 cases (18 subjects). Treatment durations ranged from 25 days to 14 months, and the ages of the subjects ranged from 34 to 78 years. Intravenous MSCs treatment was associated with a consistent and measurable increase in peripheral blood telomere length. These results support the hypothesis that telomere length can be used as an outcome biomarker and patient selection criterion for MSCs-based antiaging therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.